Literature DB >> 22301479

Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.

Elizabeth H Doby1, Daniel K Benjamin, Anne J Blaschke, Robert M Ward, Andrew T Pavia, Paul L Martin, Timothy A Driscoll, Michael Cohen-Wolkowiez, Cassandra Moran.   

Abstract

Voriconazole is the treatment of choice for invasive aspergillosis and its use is increasing in pediatrics. Minimal pharmacokinetic data exist in young children. We report voriconazole concentrations for 10 children <3 years of age and pharmacokinetic parameters for 1 infant who had therapeutic drug monitoring performed. Trough concentrations were unpredictable based on dose, highlighting the need to follow values during therapy.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22301479      PMCID： PMC3356483          DOI： 10.1097/INF.0b013e31824acc33

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  22 in total

1.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

2.  Voriconazole serum concentrations in an infant treated for Trichosporon beigelii infection.

Authors:  Holly D Maples; Cindy D Stowe; Suzanne L Saccente; Richard F Jacobs
Journal:  Pediatr Infect Dis J       Date:  2003-11       Impact factor: 2.129

3.  Intravenous voriconazole therapy in a preterm infant.

Authors:  Kendre'a M Muldrew; Holly D Maples; Cindy D Stowe; Richard F Jacobs
Journal:  Pharmacotherapy       Date:  2005-06       Impact factor: 4.705

4.  Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.

Authors:  Roberto P Santos; Pablo J Sánchez; Asuncion Mejias; Daniel K Benjamin; Thomas J Walsh; Sanjay Patel; Hasan S Jafri
Journal:  Pediatr Infect Dis J       Date:  2007-04       Impact factor: 2.129

5.  Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight.

Authors:  K Frankenbusch; F Eifinger; A Kribs; J Rengelshauseu; B Roth
Journal:  J Perinatol       Date:  2006-08       Impact factor: 2.521

Review 6.  Pharmacokinetic/pharmacodynamic profile of voriconazole.

Authors:  Ursula Theuretzbacher; Franziska Ihle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.

Authors:  Magdalena Gerin; Nizar Mahlaoui; Caroline Elie; Fanny Lanternier; Marie-Elisabeth Bougnoux; Stéphane Blanche; Olivier Lortholary; Vincent Jullien
Journal:  Ther Drug Monit       Date:  2011-08       Impact factor: 3.681

Review 8.  Voriconazole: a new triazole antifungal agent.

Authors:  Leonard B Johnson; Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2003-02-10       Impact factor: 9.079

9.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

Authors:  Andres Pascual; Thierry Calandra; Saskia Bolay; Thierry Buclin; Jacques Bille; Oscar Marchetti
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

10.  Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.

Authors:  Thomas J Walsh; Mats O Karlsson; Timothy Driscoll; Adriano G Arguedas; Peter Adamson; Xavier Saez-Llorens; Ajay J Vora; Antonio C Arrieta; Jeffrey Blumer; Irja Lutsar; Peter Milligan; Nolan Wood
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191
View more
  16 in total

Review 1.  Old and new: appropriate dosing for neonatal antifungal drugs in the nursery.

Authors:  Jessica Ericson; Paolo Manzoni; Daniel K Benjamin
Journal:  Early Hum Dev       Date:  2013-06       Impact factor: 2.079

Review 2.  Neonatal candidiasis: diagnosis, prevention, and treatment.

Authors:  Rachel G Greenberg; Daniel K Benjamin
Journal:  J Infect       Date:  2014-08-13       Impact factor: 6.072

3.  Administration of Voriconazole in Disseminated Talaromyces (Penicillium) Marneffei Infection: A Retrospective Study.

Authors:  Yanyin Ouyang; Shuangqi Cai; Hao Liang; Cunwei Cao
Journal:  Mycopathologia       Date:  2017-01-20       Impact factor: 2.574

4.  Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.

Authors:  Kevin M Watt; Michael Cohen-Wolkowiez; Robert M Ward; Daniel K Benjamin
Journal:  Pediatr Infect Dis J       Date:  2012-06       Impact factor: 2.129

Review 5.  Considerations in the pharmacologic treatment and prevention of neonatal sepsis.

Authors:  Chris Stockmann; Michael G Spigarelli; Sarah C Campbell; Jonathan E Constance; Joshua D Courter; Emily A Thorell; Jared Olson; Catherine M T Sherwin
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

Review 6.  Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Authors:  Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

Review 7.  Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.

Authors:  Jodi M Lestner; P Brian Smith; Michael Cohen-Wolkowiez; Daniel K Benjamin; William W Hope
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

Review 8.  Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Authors:  Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

9.  A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children.

Authors:  Nicole R Zane; Dhiren R Thakker
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

Review 10.  Treatment and prophylaxis of invasive candidiasis.

Authors:  Nidhi Tripathi; Kevin Watt; Daniel K Benjamin
Journal:  Semin Perinatol       Date:  2012-12       Impact factor: 3.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.